...
首页> 外文期刊>Circulation journal >Gender-Specific Outcome After Paclitaxel-Eluting Stent Implantation in Japanese Patients With Coronary Artery Disease – Sub-Analysis of the Japan TAXUS Express2 Post-Marketing Survey –
【24h】

Gender-Specific Outcome After Paclitaxel-Eluting Stent Implantation in Japanese Patients With Coronary Artery Disease – Sub-Analysis of the Japan TAXUS Express2 Post-Marketing Survey –

机译:日本冠状动脉疾病患者紫杉醇洗脱支架植入后的性别特异性结果–日本TAXUS Express2上市后调查的子分析–

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: ?Although previous randomized and non-randomized studies have demonstrated the safety and efficacy of paclitaxel-eluting stents (PES), a higher revascularization rate has been reported in women than in men. A sub-analysis of the TAXUS Japan Post-market Surveillance Study (TAXUS-PMS) was done to assess the influence of gender on clinical outcome. Methods and Results: ?A total of 2,132 PES-treated Japanese patients (women, n=551) from this registry were analyzed. Subjects were stratified by gender to compare 1-year clinical outcome. PES-treated women were older and more likely to have insulin-treated diabetes and hypertension. In contrast, PES-treated men were more likely to be smokers, have a previous history of myocardial infarction, and lower ejection fraction. While cardiac death, myocardial infarction and stent thrombosis were similar between men and women, major cardiac events tended to be lower in women than in men (6.4% vs. 8.8%, P=0.08). Although women had significantly smaller reference vessel size (2.46±0.53mm vs. 2.59±0.60mm, P
机译:背景:尽管先前的随机和非随机研究已证明紫杉醇洗脱支架(PES)的安全性和有效性,但据报道女性的血运重建率高于男性。对TAXUS日本上市后监测研究(TAXUS-PMS)进行了子分析,以评估性别对临床结局的影响。方法和结果:总共分析了来自该登记处的2,132例接受PES治疗的日本患者(女性,n = 551)。按性别对受试者进行分层,以比较一年的临床结局。经PES治疗的女性年龄较大,并且更有可能接受胰岛素治疗的糖尿病和高血压。相比之下,经PES治疗的男性更可能是吸烟者,既往有心肌梗塞病史,且射血分数较低。尽管男女之间的心源性死亡,心肌梗塞和支架血栓形成相似,但女性的主要心脏事件往往比男性要低(6.4%比8.8%,P = 0.08)。尽管女性的参考血管尺寸明显较小(2.46±0.53mm对2.59±0.60mm,P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号